专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20190169188A1 ERGOLINE COMPOUNDS AND USES THEREOF 审中-公开
公开(公告)号：US20190169188A1
公开(公告)日：2019-06-06
申请号：US16171124
申请日：2018-10-25
申请人： Xoc Pharmaceuticals, Inc.
发明人： Thomas Armer , Geoff McKinley , Scott Borland , Miguel Guzman , Ármin Szabolcs , János Gerencser
IPC分类号： C07D471/06 , C07D495/06
CPC分类号： C07D471/06 , C07D495/06
摘要： Provided herein are ergoline compounds and pharmaceutical compositions thereof. In some embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1A, 5-HT1B and 5-HT1D receptors without agonizing the 5-HT2B receptor using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HT2B adrenergic alpha2A and/or the alpha2B receptors using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the D2 and D3 receptor using the compounds and pharmaceutical compositions disclosed herein.

2. 发明申请

US20180298001A1 ERGOLINE COMPOUNDS AND USES THEREOF 审中-公开
公开(公告)号：US20180298001A1
公开(公告)日：2018-10-18
申请号：US16016474
申请日：2018-06-22
申请人： Xoc Pharmaceuticals, Inc.
发明人： Thomas Armer , Geoff McKinley , Scott Borland , Miguel Guzman , Ármin Szabolcs , János Gerencser
IPC分类号： C07D471/06 , C07D495/06
CPC分类号： C07D471/06 , C07D495/06
摘要： Provided herein are ergoline compounds and pharmaceutical compositions thereof. In some embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1A, 5-HT1B and 5-HT1D receptors without agonizing the 5-HT2B receptor using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HT2B adrenergic alpha2A and/or the alpha2B receptors using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the D2 and D3 receptor using the compounds and pharmaceutical compositions disclosed herein.

3. 发明授权

US09951070B2 Ergoline compounds and uses thereof 有权
公开(公告)号：US09951070B2
公开(公告)日：2018-04-24
申请号：US15449018
申请日：2017-03-03
申请人： Xoc Pharmaceuticals, Inc.
发明人： Thomas Armer , Geoff McKinley , Scott Borland , Miguel Guzman , Ármin Szabolcs , János Gerencser
IPC分类号： C07D471/06 , C07D495/06
CPC分类号： C07D471/06 , C07D495/06
摘要： Provided herein are ergoline compounds and pharmaceutical compositions thereof. In some embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1A, 5-HT1B and 5-HT1D receptors without agonizing the 5-HT2B receptor using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HT2B adrenergic alpha2A and/or the alpha2B receptors using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the D2 and D3 receptor using the compounds and pharmaceutical compositions disclosed herein.

4. 发明申请

US20170334891A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS 审中-公开
公开(公告)号：US20170334891A1
公开(公告)日：2017-11-23
申请号：US15522373
申请日：2015-10-28
申请人： GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
发明人： Steven David KNIGHT , Kenneth Allen NEWLANDER , Xinrong TIAN
IPC分类号： C07D409/14 , C07D409/12 , C07D413/14 , C07D495/06
CPC分类号： C07D409/14 , C07D409/12 , C07D413/14 , C07D495/04 , C07D495/06
摘要： This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.

5. 发明申请

US20170233404A1 ISOERGOLINE COMPOUNDS AND USES THEREOF 有权
公开(公告)号：US20170233404A1
公开(公告)日：2017-08-17
申请号：US15586255
申请日：2017-05-03
申请人： Xoc Pharmaceuticals, Inc.
发明人： Thomas Armer , Geoff McKinley , Scott Borland , Miguel Guzman
IPC分类号： C07D495/06 , C07D471/06
CPC分类号： C07D457/12 , A61P25/06 , A61P25/22 , A61P25/28 , C07D471/06 , C07D495/06
摘要： Provided herein are isoergoline compounds and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1A, 5-HT1B and 5-HT1D receptors without agonizing the 5-HT2B receptor using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HT2B adrenergic alpha2A and/or the alpha2B receptors using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the D2 and D3 receptor using the compounds and pharmaceutical compositions disclosed herein.

6. 发明申请

US20170233387A1 ISOERGOLINE COMPOUNDS AND USES THEREOF 有权
公开(公告)号：US20170233387A1
公开(公告)日：2017-08-17
申请号：US15586244
申请日：2017-05-03
申请人： Xoc Pharmaceuticals, Inc.
发明人： Thomas Armer , Geoff McKinley , Scott Borland , Miguel Guzman
IPC分类号： C07D457/12
CPC分类号： C07D457/12 , A61P25/06 , A61P25/22 , A61P25/28 , C07D471/06 , C07D495/06
摘要： Provided herein are isoergoline compounds and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1A, 5-HT1B and 5-HT1D receptors without agonizing the 5-HT2B receptor using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HT2B adrenergic alpha2A and/or the alpha2B receptors using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the D2 and D3 receptor using the compounds and pharmaceutical compositions disclosed herein.

7. 发明授权

US09556200B2 Tricyclic compound 有权
标题翻译：三环化合物
公开(公告)号：US09556200B2
公开(公告)日：2017-01-31
申请号：US14381347
申请日：2013-03-06
申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED
发明人： Tomokazu Kusumoto , Shigekazu Sasaki , Hironobu Maezaki
IPC分类号： A61K31/55 , C07D487/06 , C07D495/06 , C07D491/06
CPC分类号： C07D495/06 , C07D487/06 , C07D491/06
摘要： The present invention provides a compound having a superior serotonin 5-HT2C receptor activating action.The present invention relates to a compound represented by the formula (1) wherein ring A is an aromatic carbocycle optionally having substituent(s) or an aromatic heterocycle optionally having substituent(s), X is —N(R1)—, —O— or the like, when ring A is an aromatic carbocycle optionally having substituent(s), then R1 is a hydrogen atom, an alkyl group optionally having substituent(s), or the like, and when ring A is an aromatic heterocycle optionally having substituent(s), then R1 is a hydrogen atom, an alkyl group optionally having substituent(s), a cycloalkyl group optionally having substituent(s), or the like, is a single bond or a double bond, and n is an integer of 0, 1 or 2, or a salt thereof.
摘要翻译：本发明提供具有优良的5-羟色胺5-HT 2c受体激活作用的化合物。本发明涉及由式（1）表示的化合物，其中环A是任选具有取代基的芳族碳环或任选具有取代基的芳族杂环，X是-N（R 1） - ， - O - 当环A为任选具有取代基的芳族碳环，则R 1为氢原子，任选具有取代基的烷基等，当环A为任选的芳香族杂环时，具有取代基，则R 1为氢原子，任选具有取代基的烷基，任选具有取代基的环烷基等为单键或双键，n为 0,1或2的整数，或其盐。

8. 发明授权

US09428518B2 Perylenemonoimide and naphthalenemonoimide derivatives and their use in dye-sensitized solar cells 有权
标题翻译：过苯二甲酰亚胺和萘二甲酰亚胺衍生物及其在染料敏化太阳能电池中的应用
公开(公告)号：US09428518B2
公开(公告)日：2016-08-30
申请号：US14772488
申请日：2014-03-12
申请人： BASF SE , Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
发明人： Henrike Wonneberger , Neil Gregory Pschirer , Flavio Luiz Benedito , Ingmar Bruder , Robert Send , Yulian Zagranyarski , Chen Li , Klaus Muellen , Long Chen , Artem Nikolaevich Skabeev
IPC分类号： C07D471/08 , C07D493/08 , H01L51/42 , C07D491/06 , H01L51/00 , C07D221/04 , C07D471/06 , C07D493/06 , C07D495/06 , C09B5/62 , H01G9/20
CPC分类号： C07D491/06 , C07D221/04 , C07D471/06 , C07D493/06 , C07D495/06 , C09B5/62 , C09B57/08 , H01G9/2031 , H01G9/2059 , H01L51/0053 , H01L51/006 , H01L51/0061 , H01L51/4226 , Y02E10/542 , Y02E10/549 , Y02P70/521
摘要： A sensitizer in a dye-sensitized solar cell, including a compound of formula (I′) where: R1 and R2 are hydrogen, a halogen, an alkyl group, a cycloalkyl group, an aryl group, a hetaryl group, an alkoxy group, an aryloxy group, an arylthio group, a hetaryloxy group, a hetarylthio group, a diarylamino group, or a dialkylamino group; m, n are each independently an integer from 0-4; X is sulfur, oxygen, or NR3, where R3 is hydrogen, an alkyl group, a cycloalkyl group, an aryl group, or a hetaryl group; Y1 is oxygen or N—Z-A, where A is —COOM, —SO3M, or —PO3M, where M is hydrogen, an alkali metal cation, or [NR′]4+, where each R′ is independently hydrogen or an alkyl group, and where Z is C1-C6-alkylene or 1,4-phenylene, where the phenylene radical is optionally substituted by one or more alkyl, nitro, cyano, and halogen substituents.
摘要翻译：染料敏化太阳能电池中的敏化剂，包括式（I'）化合物，其中：R1和R2是氢，卤素，烷基，环烷基，芳基，杂芳基，烷氧基，芳氧基，芳硫基，杂芳氧基，杂芳硫基，二芳基氨基或二烷基氨基; m，n各自独立地为0-4的整数; X是硫，氧或NR 3，其中R 3是氢，烷基，环烷基，芳基或杂芳基; Y1是氧或N-ZA，其中A是-COOM，-SO3M或-PO3M，其中M是氢，碱金属阳离子或[NR'] 4+，其中每个R'独立地是氢或烷基并且其中Z是C 1 -C 6亚烷基或1,4-亚苯基，其中亚苯基任选被一个或多个烷基，硝基，氰基和卤素取代基取代。

9. 发明授权

US09123902B2 Semiconductor compound 有权
标题翻译：半导体化合物
公开(公告)号：US09123902B2
公开(公告)日：2015-09-01
申请号：US13024446
申请日：2011-02-10
申请人： Anthony J. Wigglesworth , Yiliang Wu , Ping Liu
发明人： Anthony J. Wigglesworth , Yiliang Wu , Ping Liu
IPC分类号： H01L51/00 , C07D495/06 , H01L51/05
CPC分类号： H01L51/0074 , C07D495/06 , H01L51/0076 , H01L51/0541 , H01L51/0545
摘要： A thiaxanthenothiaxanthene compound of Formula (I): wherein R1 to R10 are independently selected from the group consisting of hydrogen, an alkyl group, a substituted alkyl group, an alkoxy group, an alkylthio group, an alkenyl group, a substituted alkenyl group, an ethynyl group, a substituted ethynyl group, an aryl group, a substituted aryl group, a heteroaryl group, a substituted heteroaryl group, a trialkylsilyl group, a fluorohydrocarbon group, a cyano group and a halogen; and wherein the semiconductor of Formula (I) is predominantly crystalline or liquid crystalline. The compounds are designed to ensure air stability, good solubility, and high mobility.
摘要翻译：式（I）的噻吩并噻吩类化合物：其中R 1至R 10独立地选自氢，烷基，取代的烷基，烷氧基，烷硫基，烯基，取代的烯基，乙炔基，取代乙炔基，芳基，取代芳基，杂芳基，取代杂芳基，三烷基甲硅烷基，氟代烃基，氰基和卤素; 并且其中式（I）的半导体主要是结晶或液晶。这些化合物被设计成确保空气稳定性，良好的溶解性和高迁移率。

10. 发明申请

US20150065671A1 ORGANIC SEMICONDUCTOR MATERIAL 有权
标题翻译：有机半导体材料
公开(公告)号：US20150065671A1
公开(公告)日：2015-03-05
申请号：US14391041
申请日：2013-04-16
申请人： SUMITOMO CHEMICAL COMPANY, LIMITED
发明人： Hiroki Terai
IPC分类号： H01L51/00 , H01L51/05
CPC分类号： H01L51/0036 , C07D495/06 , C08G61/123 , C08G61/126 , C08G2261/1412 , C08G2261/148 , C08G2261/3223 , C08G2261/3246 , C08G2261/344 , C08G2261/354 , C08G2261/411 , C08G2261/92 , H01L51/0043 , H01L51/0074 , H01L51/0504 , H01L51/0541 , H01L51/0545 , H01L51/42
摘要： A compound represented by the formula (1). A polymer compound comprising the compound. An organic semiconductor material comprising the compound or the polymer compound. An organic semiconductor device comprising an organic layer comprising the organic semiconductor material. An organic transistor comprising a source electrode, a drain electrode, a gate electrode and an active layer, wherein the active layer comprises the organic semiconductor material.
摘要翻译：由式（1）表示的化合物。包含该化合物的高分子化合物。包含该化合物或高分子化合物的有机半导体材料。一种包含有机层的有机半导体器件，包括有机半导体材料。一种有机晶体管，包括源电极，漏电极，栅电极和有源层，其中有源层包括有机半导体材料。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式